HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lauder Q2 Sales Pummeled By China Closures, US Skin-Care Slowdown

Executive Summary

The Estee Lauder Companies, Inc. reported a 17% decline in fiscal 2023 second quarter sales due to pandemic-related closures in China as well as a slowdown in orders of US skin-care products. But the company says both its Chinese and US markets should be “growth drivers” in the second half of the year as markets open up and new innovations kick in.

You may also be interested in...

Estee Lauder Companies’ Post-Pandemic Struggle Continues In Q3; Travel Retail Down 45%

Lauder lowers its fiscal 2023 full-year sales guidance a third time as travel retail recovery in Asia lags and global travel retail sales plunge 45% organically. On the bright side, the rest of the firm’s business grew 10%.

‘Lipstick Effect’ Holding In 2023 Despite Continuing Price Escalation – Catalina Marketing

Consumers continued to spend more on beauty products in January 2023 in US mass retail doors despite rising prices across face makeup, eye makeup and lipstick segments, according to market intelligence and consulting firm Catalina Marketing.

Lauder Lowers FY23 Outlook On ‘Temporary Pause’ In China, Tightening Of US Inventory

Estee Lauder Companies says fiscal 2023 second-quarter sales will decline high double digits due to ongoing COVID-19 restrictions in China, tightening inventory by some US retailers, and a strong US dollar. The firm expects improvement in the back half of the year, but has adjusted full-year guidance.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts